Combined UT-15C with PDE5-I or ERA 2017-03-03T15:48:47+00:00

Clinical Trials

August 27, 2013

Trial of the Early Combination of Oral Treprostinil With a PDE-5 Inhibitor or ERA in Subjects with Pulmonary Arterial Hypertension

  • Study Sponsor: United Therapeutics Corporation
  • Institution: United Therapeutics Corporation
  • Start Date: 07/2012
  • End Date: 08/2016
  • Design: Placebo-controlled
  • Age range (years): from 18 to 75
  • Type of PH
    • IPAH
    • Heritable – APAH
    • CTD – APAH
    • CHD – APAH
    • Toxic – APAH
    • HIV – APAH
  • Study Duration for individual patient: 24 weeks
  • Contact: Meredith Howell at 919-485-8350
  • Listing on clinicaltrials.gov